Starling Oncology, Inc.
No SEC Form 4 filings for $DFPH in the last 30 days.
See all $DFPH insider activity →Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
Hively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DFPH (Starling Oncology, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DFPH coverage spans corporate actions, insider activity and earnings.
Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
Hively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, su
This is a disclosed insider open-market purchase, but it is not large enough to imply a fundamental change by itself.
AlphAI scores every news story that mentions DFPH with an AI model for sentiment and relevance, and aggregates insider trades from Starling Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
2 min readStarling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
4 min readHively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readStarling Oncology, Inc. (STLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, su
2 min readChernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
1 min read